A Single-Pot Template Reaction Towards a Manganese-Based T(1) Contrast Agent.

A Single-Pot Template Reaction Towards a Manganese-Based T(1) Contrast Agent.
复制标题

DOI:
10.1002/anie.202100885
复制
发表时间:
2021-05-03
期刊:
Angewandte Chemie (International ed. in English)
影响因子:
--
通讯作者:
Stasiuk GJ
Stasiuk GJ
中科院分区:
其他
文献类型:
--
作者:
Anbu S;Hoffmann SHL;Carniato F;Kenning L;Price TW;Prior TJ;Botta M;Martins AF;Stasiuk GJ

文献摘要

参考文献

被引文献

相似文献

锰基造影剂(MnCA)已成为Gd基造影剂(GDCA)的合适替代品。然而,由于它们的动力学不稳定性和繁琐的合成过程,只有少数的MnCA已经在临床上应用。在这项工作中,我们采用了一种高度创新的单盆模板合成策略来开发一种MnCA,MnLMe,并研究了 体外最重要的物理化学性质。在介质(2 0和 MHZ)和强磁场(30 0和40 0 MHZ)下,MnLMe都表现出最佳的r1弛豫性能,与牛血清白蛋白(Ka=4.2×10 3 M−1)结合后,r1b=2 1.1 mm−1 S−1(2 0 Mhz,2 98 K,pH 7.4)得到增强。在 体内的研究表明,MnLMe通过肾脏排泄被完整地清除到膀胱中,并且与商业的GDCA Magnevist相比,具有更长的血半衰期。MnLMe作为一种新型的磁共振造影剂具有广阔的应用前景。我们提出了一种用于锰基磁共振造影剂MnLMe的单锅模板合成策略。MnLMe对锌的跨金属迁移反应高度惰性,在与血清白蛋白的非共价相互作用下表现出增强的T1弛豫性能。在 体内的研究表明,与商业上可用的造影剂Magnevist相比,肝脏的对比度增强程度更高,血液半衰期更长。MnLMe显示出作为血池试剂的巨大潜力。
Manganese‐based contrast agents (MnCAs) have emerged as suitable alternatives to gadolinium‐based contrast agents (GdCAs). However, due to their kinetic lability and laborious synthetic procedures, only a few MnCAs have found clinical MRI application. In this work, we have employed a highly innovative single‐pot template synthetic strategy to develop a MnCA, MnLMe, and studied the most important physicochemical properties in vitro. MnLMe displays optimized r 1 relaxivities at both medium (20 and 64 MHz) and high magnetic fields (300 and 400 MHz) and an enhanced r 1 b=21.1 mM−1 s−1 (20 MHz, 298 K, pH 7.4) upon binding to BSA (K a=4.2×103 M−1). In vivo studies show that MnLMe is cleared intact into the bladder through renal excretion and has a prolonged blood half‐life compared to the commercial GdCA Magnevist. MnLMe shows great promise as a novel MRI contrast agent. We present a single‐pot template synthesis strategy for a manganese‐based MRI contrast agent, MnLMe. MnLMe is highly inert toward zinc‐transmetallation and displays enhanced T 1 relaxivity upon non‐covalent interaction with serum albumin. In vivo studies show higher contrast enhancement in the liver and longer blood half‐life than that of the commercially available contrast agent Magnevist. MnLMe shows great potential for use as a blood pool agent.
DOI: 10.1039/c1dt10543d
发表时间: 2011-01-01
影响因子: 4
作者:
Drahos, Bohuslav;Pniok, Miroslav;Toth, Eva
通讯作者: Toth, Eva
DOI: 10.1021/ic201935r
发表时间: 2011-12-19
影响因子: 4.6
作者:
Drahos, Bohuslav;Kotek, Jan;Toth, Eva
通讯作者: Toth, Eva
DOI: 10.1097/rli.0b013e3181ee5a9e
发表时间: 2010-10-01
影响因子: 6.7
作者:
Dumas, Stephane;Jacques, Vincent;Caravan, Peter
通讯作者: Caravan, Peter
DOI: 10.1161/hc3601.094303
发表时间: 2001-09-11
期刊: CIRCULATION
影响因子: 37.8
作者:
Flacke, S;Fischer, S;Lanza, GM
通讯作者: Lanza, GM